Clinical predictors of early infarct-related artery patency following thrombolytic therapy: Importance of body weight, smoking history, infarct- related artery and choice of thrombolytic regimen: The GUSTO-I experience

Journal of the American College of Cardiology

Volumn 32, Issue 3, 1998, Pages 641-647

  Lundergan, Conor F ^a   Reiner, Jonathan S ^a   McCarthy, William F ^a   Coyne, Karin S ^a   Califf, Robert M ^b   Ross, Allan M ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOGRAPHY; ARTICLE; BODY WEIGHT; CORONARY ARTERY BLOOD FLOW; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFICACY; FEMALE; FIBRINOLYTIC THERAPY; HEART VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; TREATMENT OUTCOME;

AGED; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; DRUG THERAPY, COMBINATION; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; STREPTOKINASE; SURVIVAL RATE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VASCULAR PATENCY; VENTRICULAR FUNCTION, LEFT;

EID: 0031696968     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00278-2     Document Type: Article

References (28)

1. Simes R.J., Topol E.J., Holmes D.R., et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Circulation. 91:1995;1923-1928.
2. Becker R.C. Hemodynamic, mechanical, and metabolic determinants of thrombolytic efficacy a theoretic framework for assessing the limitations of thrombolysis in cardiogenic shock . Am Heart J. 125:1993;919-929.
3. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Eng J Med. 329:1993;1615-1621.
4. Chesebro J.H., Knatterud G., Roberts R., et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I a comparison between intravenous tissue plasminogen activator and intravenous streptokinase . Circulation. 76:1987;142-154.
5. Armitage P., Berry G. Statistical Methods. 3rd edition. 1994;Blackwell, Oxford.
6. Freund R.J., Littell R.C. The SAS System for Regression. 2nd edition. 1991;SAS Institute, Inc, Cary, NC.
7. Lee K.L., Woodlief M.S., Topol E.J., et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction Results from an international trial of 41,021 patients . Circulation. 91:1995;1659-1668.
8. Miller M.E., Langefeld C.D. Validation of probabilistic predictions. Med Decis Making. 13:1993;49-58.
9. SAS Institute Inc. Logistic Regression Examples Using the SAS System. Version 6, 1st edition, Cary, NC: SAS Institute Inc., 1995.
10. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Eng J Med. 329:1993;673-682.
11. Neuhaus K.L., Feuerer W., Jeep-Tebbe S., et al. Improved thrombolysis with a modified dose regimen of recombinant tissue type plasminogen activator. J Am Coll Cardiol. 14:1989;1566-1569.
12. Karagounis L.A., Anderson J.L., Sorenson S.G., et al. Relation of reperfusion success with anistreplase or alteplase in acute myocardial infarction to body weight. Am J Cardiol. 73:1994;16-22.
13. Bates E.R., Califf R.M., Stack R.S., et al. Thrombolysis and angioplasty in myocardial infarction (TAMI-I) trial influence of infarct location on arterial patency, left ventricular function and mortality . J Am Coll Cardiol. 13:1989;12-18.
14. Anderson J.L., Sorenson S.G., Moreno F.L., et al. Multicenter patency trial of intravenous anistreplase compared with streptokinase in acute myocardial infarction. Circulation. 83:1991;126-140.
15. Pacouret G., Charbonnier B., Curien N.D., et al. Invasive reperfusion study II Multicenter european randomized trial of anistreplase vs streptokinase in acute myocardial infarction . Eur Heart J. 12:1991;179-185.
16. Leizorovicz A., Boissel J.P., Robert F. Coronary reperfusion rates in acute myocardial infarction patients after thrombolytic treatment with anistreplase correlation with the delay from onset of symptoms to treatment: a review of 424 case records of patients admitted to coronary reperfusion studies with anistreplase . J Cardiovasc Pharm. 19:1992;34-39.
17. Tendera M.P., Campbell W.B., Tennant S.N., et al. Factors influencing probability of reperfusion with intracoronary ostial infusion of thrombolytic agent in patients with acute myocardial infarction. Circulation. 71:1985;124-128.
18. Barbash G.I., Reiner J.S., White H.D., et al. Evaluation of the paradoxical effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction mechanism of the "smokers' paradox" from the GUSTO-I trial, with angiographic insights . J Am Coll Cardiol. 26:1995;1222-1229.
19. Gomez M.A., Karagounis L.A., Allen A., et al. Effect of cigarette smoking on coronary patency after thrombolytic therapy for myocardial infarction. Am J Cardiol. 72:1993;373-378.
20. Kennedy J.W., Gensini G.G., Timmis G.C., et al. Acute myocardial infarction treated with intracoronary streptokinase a report of the society for cardiac angiography . Am J Cardiol. 55:1985;871-877.
21. Hogg K.J., Gemmill J.D., Burns J.M.A., et al. Angiographic patency of anistreplase vs streptokinase in acute myocardial infarction. Lancet. 335:1990;254-258.
22. Anderson J.L., Rothbard R.L., Hackworthy R.A., et al. Multicenter reperfusion trial of intravenous anisolyated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction controlled comparison with intracoronary streptokinase . J Am Coll Cardiol. 11:1988;1153-1163.
23. Bode C., Smalling R.W., Berg G., et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation. 94:1996;891-898.
24. Lenderink T., Simoons M.L., Van ES G.A., et al. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. Circulation. 92:1995;1110-1116.
25. Reiner J.S., Lundergan C.F., Fung A., et al. Evolution of early TIMI 2 flow after thrombolysis for acute myocardial infarction. Circulation. 94:1996;2441-2446.
26. Smalling R.W., Schumacher R., Morris D., et al. Improved infarct related artery patency after high dose, weight adjusted, rapid infusion of tissue plasminogen activator in myocardial infarction results of a multicenter randomized trial of two dosage regimens . J Am Coll Cardiol. 15:1990;915-921.
27. Gore J.M., Granger C.B., Simoons M.L., et al. Stroke after thrombolysis Mortality and functional outcomes in the GUSTO-1 trial . Circulation. 92:1995;2811-2818.
28. LeGall J.R. Modelling the severity of illness in ICU patients. JAMA. 272:1994;1050.